Biblio
Older Patients with Acute Myeloid Leukemia Deserve Individualized Treatment. Curr Oncol Rep. 2022.
. Early assessment of clofarabine effectiveness applying measurable residual disease, including AML stem cells. Blood. 2020.
. EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies. ESMO Open. 2020;5(1).
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission. N Engl J Med. 2020;383(26):2526-2537.
.
IGFBP7 Induces Differentiation and Loss of Survival of Human Acute Myeloid Leukemia Stem Cells without Affecting Normal Hematopoiesis. Cell Rep. 2018;25(11):3021-3035.e5.
Leukemic Stem Cell Frequency: A Strong Biomarker for Clinical Outcome in Acute Myeloid Leukemia. PLoS One. 2014;9(9):e107587.